# US 2021/0069150 A1 · Modified release formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069150 A1
- Document ID: US20210069150A1
- Status: Published application
- Kind: A1
- Application number: 16/898,071
- Filed: 2020-06-10
- Published: 2021-03-11
- Earliest claimed: 2013-06-12
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Bruno GALLI; Jean-Marie GLANTZMANN; Arnaud GRANDEURY; Klaus-Peter MOLL; Martin MUELLER- ZSIGMONDY; Karsten PUTZBACH; Dirk SPICKERMANN; Hubert THOMA; Mike UFER
- Web page: https://patentgrep.com/patent/US20210069150A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61J 3/02: into the form of powders (pulverising in general B02C)
- A61J 3/10: into the form of compressed tablets (tablet presses B30B11/00)
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1682: {Processes}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 9/5089: {Processes}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Drug products in the form of modified release formulations comprising the drug substance (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

## Claims

### Claim 1

A stable modified release formulation comprising (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form as active pharmaceutical ingredient and a modified release agent, such that the active pharmaceutical ingredient is released from the formulation in a controlled fashion over a period of 6 hours, or over a period of 7 hours, so that at least 80% of the active pharmaceutical ingredient has been released at the end of this period.

### Claim 2 (depends on 1)

The modified release formulation according to claim 1 having the following release characteristics in water: about 14% to about 20% after 60 minutes; about 51% to about 61% after 180 minutes; about 67% to about 77% after 240 minutes; about 90% to about 95% after 360 minutes; and about 95% to about 99% after 420 minutes. The before mentioned release characteristics are obtained by using standard dissolution rate equipment (paddle according to e.g. USP) at 100 rpm with 900 ml of Water+0.5% LDAO.

### Claim 3 (depends on 1, 2)

The modified release formulation according to claim 1 or 2, wherein the modified release agent is hydroxy propyl methylcellulose.

### Claim 4 (depends on 3)

The modified release formulation according to claim 3 wherein the drug substance has a particle size distribution of ×10≤50 μm, ×50≤100 μm and ×90≤200 μm.

### Claim 5 (depends on 4)

The modified release formulation according to claim 4 that exhibits a similar or decreased release rate in ethanol containing media as compared to a aqueous media with 0.5% LDAO.

### Claim 6

The modified release formulation according to any of the previous claims further comprising a coating.

### Claim 7

The modified release formulation according to any of the previous claims in form of a single unit dosage form comprising about 25 mg to about 250 mg (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form, about 69 mg to about 135 mg hypromellose (type 2208 characterized by viscosities between about 80 to about 120 cP (20° C.)), about 20 mg to about 160 mg lactose monohydrate, about 3 mg to about 38 mg sodium starch glycolate, about 2 mg to about 4.5 mg Magnesium stearate and about 1 mg to about 2.2 mg colloidal silicon dioxide.

### Claim 8 (depends on 7)

The modified release formulation according to claim 7 wherein (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester in free base form is present in an amount of about 25-250 mg.

### Claim 9

The modified release formulation according to any of the previous claims in single unit dosage form comprising equal to or less than 100 mg AFQ056 compressed to round tablets with a diameter of about 8 mm.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The modified release formulation according to claims 1-8 in single unit dosage form comprising more than 100 mg AFQ056 compressed to round tablets with a diameter of about 11 mm.

### Claim 11 (depends on 1)

A process for the production of a modified release formulation of claim 1, comprising
(i) mixing AFQ056 with filler, binder and disintegrant in a high shear granulator
(ii) adding purified water under mixing
(iii) kneading the mixture in a high shear granulator
(iv) passing the granulate through a screen using a screening mill
(v) drying the granulate in a fluid bed dryer
(vi) mixing the dry granulate with a modified release agent, filler and glidant followed by consecutive sieving using screening mill and mixing in a diffusion mixer
(vii) sieving a lubricant and adding to the mixture from the diffusion mixer
(viii) forming the composition

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The modified release formulation according to claim 1-10 for use in the treatment of Parkinson's disease L-dopa induced dyskinesia, Fragile X syndrome (Martin-Bell syndrome), dyskinesia in Fragile X syndrome, obsessive compulsory disorders, autism, cystitis, and for the treatment, prevention or delay of progression of acute, traumatic and chronic degenerative processes of the nervous system, such as Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases such as schizophrenia and anxiety, depression, pain, itch and drug abuse such as alcohol and nicotine abuse and cocaine use disorders.
